Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 4
2001 2
2002 11
2003 15
2004 13
2005 15
2006 14
2007 18
2008 22
2009 21
2010 24
2011 30
2012 37
2013 30
2014 32
2015 45
2016 39
2017 27
2018 24
2019 41
2020 40
2021 54
2022 37
2023 45
2024 20

Text availability

Article attribute

Article type

Publication date

Search Results

563 results

Results by year

Filters applied: . Clear all
Page 1
Current treatment of IgA nephropathy.
Floege J, Rauen T, Tang SCW. Floege J, et al. Semin Immunopathol. 2021 Oct;43(5):717-728. doi: 10.1007/s00281-021-00888-3. Epub 2021 Sep 8. Semin Immunopathol. 2021. PMID: 34495361 Free PMC article. Review.
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ, Jayne DRW, Jha V, Liew A, Liu ZH, Mejía-Vilet JM, Nester CM, Radhakrishnan J, Rave EM, Reich HN, Ronco P, Sanders JF, Sethi S, Suzuki Y, Tang SCW, Tesar V, Vivarelli M, Wetzels JFM, Lytvyn L, Craig JC, Tunnicliffe DJ, Howell M, Tonelli MA, Cheung M, Earley A, Floege J. Rovin BH, et al. Among authors: floege j. Kidney Int. 2021 Oct;100(4):753-779. doi: 10.1016/j.kint.2021.05.015. Kidney Int. 2021. PMID: 34556300 Free article.
Decoding myofibroblast origins in human kidney fibrosis.
Kuppe C, Ibrahim MM, Kranz J, Zhang X, Ziegler S, Perales-Patón J, Jansen J, Reimer KC, Smith JR, Dobie R, Wilson-Kanamori JR, Halder M, Xu Y, Kabgani N, Kaesler N, Klaus M, Gernhold L, Puelles VG, Huber TB, Boor P, Menzel S, Hoogenboezem RM, Bindels EMJ, Steffens J, Floege J, Schneider RK, Saez-Rodriguez J, Henderson NC, Kramann R. Kuppe C, et al. Among authors: floege j. Nature. 2021 Jan;589(7841):281-286. doi: 10.1038/s41586-020-2941-1. Epub 2020 Nov 11. Nature. 2021. PMID: 33176333 Free PMC article.
IgA nephropathy.
Stamellou E, Seikrit C, Tang SCW, Boor P, Tesař V, Floege J, Barratt J, Kramann R. Stamellou E, et al. Among authors: floege j. Nat Rev Dis Primers. 2023 Nov 30;9(1):67. doi: 10.1038/s41572-023-00476-9. Nat Rev Dis Primers. 2023. PMID: 38036542 Review.
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
Lafayette R, Kristensen J, Stone A, Floege J, Tesař V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich HN, Rovin BH, Barratt J; NefIgArd trial investigators. Lafayette R, et al. Among authors: floege j. Lancet. 2023 Sep 9;402(10405):859-870. doi: 10.1016/S0140-6736(23)01554-4. Epub 2023 Aug 14. Lancet. 2023. PMID: 37591292 Clinical Trial.
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H, Zhao M, Barbour S, Jardine MJ, Reich HN, Cattran D, Glassock R, Levin A, Wheeler DC, Woodward M, Billot L, Stepien S, Rogers K, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Zhang H, Perkovic V; TESTING Study Group. Lv J, et al. Among authors: floege j. JAMA. 2022 May 17;327(19):1888-1898. doi: 10.1001/jama.2022.5368. JAMA. 2022. PMID: 35579642 Free PMC article. Clinical Trial.
Primary glomerulonephritides.
Floege J, Amann K. Floege J, et al. Lancet. 2016 May 14;387(10032):2036-48. doi: 10.1016/S0140-6736(16)00272-5. Epub 2016 Feb 25. Lancet. 2016. PMID: 26921911 Review.
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators. Barratt J, et al. Among authors: floege j. Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19. Kidney Int. 2023. PMID: 36270561 Free article. Clinical Trial.
Assessing prognosis in IgA nephropathy.
Floege J, Wied S, Rauen T. Floege J, et al. Kidney Int. 2022 Jul;102(1):22-24. doi: 10.1016/j.kint.2022.04.018. Kidney Int. 2022. PMID: 35738837
563 results